Optipharm옵티팜
153710 · KOSDAQ · ₩153710 · 옵티팜
₩4,345▼ ₩30 (0.69%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩22B | ₩20B | ₩17B | ₩16B | ₩14B |
| Cost of sales | ₩17B | ₩15B | ₩13B | ₩12B | ₩11B |
| Gross profit | ₩5.6B | ₩4.9B | ₩4.2B | ₩3.7B | ₩3.7B |
| Operating income | −₩2.4B | −₩2.5B | −₩2.6B | −₩3.4B | −₩4.5B |
| Net income | −₩2.5B | −₩2.4B | −₩2.4B | −₩2B | −₩3.1B |
| Net income to shareholders | −₩2.5B | −₩2.4B | −₩2.4B | −₩2B | −₩3.1B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩41B | ₩43B | ₩39B | ₩41B | ₩41B |
| Current assets | ₩15B | ₩19B | ₩20B | ₩22B | ₩26B |
| Cash and equivalents | ₩2.3B | ₩3.6B | ₩2.3B | ₩5.6B | ₩8.2B |
| Total liabilities | ₩15B | ₩16B | ₩14B | ₩12B | ₩10B |
| Current liabilities | ₩13B | ₩13B | ₩12B | ₩9.3B | ₩7.9B |
| Borrowings | ₩10B | ₩11B | ₩9.6B | ₩7.5B | ₩5.8B |
| Total equity | ₩25B | ₩27B | ₩25B | ₩29B | ₩31B |
| Shareholders' equity | ₩25B | ₩27B | ₩25B | ₩29B | ₩31B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩1.6B | −₩595M | −₩1.7B | −₩2.4B | −₩2B |
| Capital spending | ₩2.5B | ₩1.7B | ₩1.7B | ₩4.6B | ₩725M |
| Free cash flow | −₩4.1B | −₩2.3B | −₩3.4B | −₩7B | −₩2.7B |
Consolidated where available. Amounts in won.
Also known as: Optipharm / 옵티팜 / 153710 / KRX:153710
Source: KRX statistical information